31JUL

Exeter spinout raises GBP3m for epilepsy

2 min read

12:32UTC

Neuronostics, an Exeter University spinout, raised GBP3m for BioEP, an EEG-based epilepsy biomarker, co-led by Empirical Ventures and The FSE Group with an Innovate UK grant.

← Back to Humanoid hit $1.35bn on a customer order Jump to analysis ↓

TechnologyDeveloping

Key takeaway

Neuronostics paired a specialist fund with an Innovate UK grant to raise in the shrinking spinout tier.

Neuronostics, a University of Exeter spinout, raised GBP3m for BioEP, a digital biomarker that reads routine EEG (electroencephalogram, a recording of the brain's electrical activity) to help diagnose epilepsy without waiting for a seizure ¹. Empirical Ventures, a UK health-specialist investor, and The FSE Group, a regional fund manager, co-led, with the British Business Bank, Ascension, QantX, New Wave and Bristol angels, blended with a GBP400k Innovate UK Investor Partnerships grant, a government co-investment programme.

The round sits in exactly the sub-GBP5m spinout tier the national tracker shows contracting sharply in 2025 . A specialist fund co-led it and Innovate UK grant money topped it up.

The Innovate UK grant matches private capital rather than replacing it, so GBP400k de-risks the private cheques around it, a different instrument from the VCT tax relief April's change cut. Blended public-grant-plus-equity rounds like this are how the thin end of the spinout pipeline is being held together one deal at a time.

Deep Analysis

In plain English

Neuronostics grew out of research at the University of Exeter. It has built BioEP, a tool that reads routine brain-wave recordings, known as EEGs, to help doctors diagnose epilepsy faster and without more invasive tests. The company raised £3m from two co-lead investors, plus a £400k top-up grant from Innovate UK, a government body that part-funds promising new British technology.

Source Landscape

This story draws on neutral-leaning sources

At £3m plus a £400k grant, Neuronostics' total funding of £3.4m is modest for a diagnostics platform that still needs clinical validation before wider NHS adoption, leaving little room for delay.

The grant covers roughly one-eighth of the round, which shows how thin Innovate UK's remaining early-stage funding pool has become relative to the private capital now doing most of the work that public grants used to carry alone.

Consensus view: The Wellcome Trust's health-innovation funding team sees blended structures like Neuronostics' £3m round, topped up with a £400k Innovate UK grant, becoming the default model for early health-tech spinouts as the retail angel base that used to fund them keeps shrinking .

Counter-view: Midlands Mindforge, the eight-university fund that wrote its first cheques in June , argues blended grant-equity financing is a stopgap: pooling several universities' capital directly into one larger regional fund still leaves an individual spinout better capitalised than a small private round patched together with a government top-up.

Key tension: Whether blended grant-and-equity financing is a durable long-term model for health-tech spinouts, or a patchwork response to a shrinking angel base that regional multi-university funds are better placed to fix.

Sources:UKTN

Mentions:Neuronostics →Radical Ventures →The FSE Group →British Business Bank →Innovate UK →Midlands Mindforge →Bristol →Fudan University →

First Reported In

Update #10 · AI takes record 44% as UK equity shrinks

UKTN· 4 Jul 2026

Read original →

Causes and effects

This Event

Exeter spinout raises GBP3m for epilepsy

A blended specialist-fund and government-grant round shows the contracting spinout tier is thinner, not closed.

Led to

Five seed rounds stir beneath megadeals

Neuronostics' £3m epilepsy-biomarker round is part of the same thin, cross-sector seed tier this week's cluster extends.

Occurred 8 Jul 2026

Read story →

Different Perspectives

Fubon Financial

Fubon Financial joined Humanoid's Series A on 21 July as a minority financial investor alongside Schaeffler and Bosch, who also hold the customer and manufacturer roles. A pure-play investor from Taipei is pricing a London robot maker on terms two German industrial groups effectively set.

NATO Innovation Fund

The Fund joined Greenjets' £30m Series A on 21 July alongside NSSIF, betting on ducted electric propulsion's civil market to fund a technology with an obvious defence application. It is backing a company that took twenty-one years to reach this stage, on the expectation that certification-cycle timelines reward patient capital over a quick return.

Prime Movers Lab

Prime Movers Lab led Humanoid's Series A on 21 July as the round's only pure financial investor, sharing the cap table with two co-investors who are also the anchor customer and the factory. That leaves the fund's usual arm's-length pricing role diluted by partners with a direct commercial stake in the valuation holding up.

Bosch and Schaeffler

Schaeffler signed what Humanoid calls the industry's largest publicly announced commercial agreement, while Bosch took equity and became contract manufacturer, filling capacity a shrinking combustion supply chain freed. Neither company has disclosed a unit count or an invoice, so their public commitment stops well short of Forbes' 100,000-unit projection.

UK founders raising seed through Series A

A London robotics founder raised $152m this week against a signed industrial customer and a reserved factory, while a Cornwall founder more typically draws a £25,000 loan from a regional fund manager. Both call it British venture funding, but one route runs through Bosch's production line and the other through diligence built for businesses too small for any VC's attention.

EQT

EQT was reported on 3 July to be in advanced talks for a further CuspAI stake on behalf of the EU's Scaleup Europe Fund, but does not appear on the round CuspAI closed. Whether Europe's own sovereign vehicle secured a position, was outbid, or withdrew is unresolved.